Represents the number of principal U.S. customers of the entity.

No definition available.

Name:	abbv_NumberOfPrincipalUSCustomers
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
Namespace Prefix:	us-gaap_
Data Type:	enum2:enumerationSetItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Segment and Geographic Area Information - Disaggregation of Revenue (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) wholesaler	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Disaggregation of Revenue
Net revenues		$ 54,318	$ 58,054	$ 56,197
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]		Total net revenues	Total net revenues	Total net revenues
Total net revenues	$ 14,301	$ 54,318	$ 58,054	$ 56,197
Number of Principal US Customers \| wholesaler		3
United States
Disaggregation of Revenue
Net revenues		$ 41,883	45,713	43,510
All other
Disaggregation of Revenue
Net revenues		3,035	4,137	5,019
Immunology \| Humira
Disaggregation of Revenue
Net revenues		14,404	21,237	20,694
Immunology \| Humira \| United States
Disaggregation of Revenue
Net revenues		12,160	18,619	17,330
Immunology \| Humira \| International
Disaggregation of Revenue
Net revenues		2,244	2,618	3,364
Immunology \| Skyrizi
Disaggregation of Revenue
Net revenues		7,763	5,165	2,939
Immunology \| Skyrizi \| United States
Disaggregation of Revenue
Net revenues		6,753	4,484	2,486
Immunology \| Skyrizi \| International
Disaggregation of Revenue
Net revenues		1,010	681	453
Immunology \| Rinvoq
Disaggregation of Revenue
Net revenues		3,969	2,522	1,651
Immunology \| Rinvoq \| United States
Disaggregation of Revenue
Net revenues		2,824	1,794	1,271
Immunology \| Rinvoq \| International
Disaggregation of Revenue
Net revenues		1,145	728	380
Oncology \| Imbruvica
Disaggregation of Revenue
Net revenues		3,596	4,568	5,408
Oncology \| Imbruvica \| United States
Disaggregation of Revenue
Net revenues		2,665	3,426	4,321
Oncology \| Imbruvica \| International
Disaggregation of Revenue
Collaboration revenues		931	1,142	1,087
Oncology \| Venclexta
Disaggregation of Revenue
Net revenues		2,288	2,009	1,820
Oncology \| Venclexta \| United States
Disaggregation of Revenue
Net revenues		1,087	1,009	934
Oncology \| Venclexta \| International
Disaggregation of Revenue
Net revenues		1,201	1,000	886
Oncology \| Epkinly
Disaggregation of Revenue
Net revenues		31
Collaboration revenues		28	0	0
Oncology \| Epkinly \| International
Disaggregation of Revenue
Net revenues		3	0	0
Aesthetics \| Botox Cosmetic
Disaggregation of Revenue
Net revenues		2,682	2,615	2,232
Aesthetics \| Botox Cosmetic \| United States
Disaggregation of Revenue
Net revenues		1,670	1,654	1,424
Aesthetics \| Botox Cosmetic \| International
Disaggregation of Revenue
Net revenues		1,012	961	808
Aesthetics \| Juvederm Collection
Disaggregation of Revenue
Net revenues		1,378	1,428	1,535
Aesthetics \| Juvederm Collection \| United States
Disaggregation of Revenue
Net revenues		519	548	658
Aesthetics \| Juvederm Collection \| International
Disaggregation of Revenue
Net revenues		859	880	877
Aesthetics \| Other Aesthetics
Disaggregation of Revenue
Net revenues		1,234	1,290	1,466
Aesthetics \| Other Aesthetics \| United States
Disaggregation of Revenue
Net revenues		1,060	1,122	1,268
Aesthetics \| Other Aesthetics \| International
Disaggregation of Revenue
Net revenues		174	168	198
Neuroscience \| Botox Therapeutic
Disaggregation of Revenue
Net revenues		2,991	2,719	2,451
Neuroscience \| Botox Therapeutic \| United States
Disaggregation of Revenue
Net revenues		2,476	2,255	2,012
Neuroscience \| Botox Therapeutic \| International
Disaggregation of Revenue
Net revenues		515	464	439
Neuroscience \| Vraylar
Disaggregation of Revenue
Net revenues		2,759	2,038	1,728
Neuroscience \| Vraylar \| United States
Disaggregation of Revenue
Net revenues		2,755	2,037	1,728
Neuroscience \| Vraylar \| International
Disaggregation of Revenue
Net revenues		4	1	0
Neuroscience \| Duodopa
Disaggregation of Revenue
Net revenues		468	458	511
Neuroscience \| Duodopa \| United States
Disaggregation of Revenue
Net revenues		97	95	102
Neuroscience \| Duodopa \| International
Disaggregation of Revenue
Net revenues		371	363	409
Neuroscience \| Ubrelvy
Disaggregation of Revenue
Net revenues		815	680	552
Neuroscience \| Ubrelvy \| United States
Disaggregation of Revenue
Net revenues		803	680	552
Neuroscience \| Ubrelvy \| International
Disaggregation of Revenue
Net revenues		12	0	0
Neuroscience \| Qulipta
Disaggregation of Revenue
Net revenues		408	158	0
Neuroscience \| Qulipta \| United States
Disaggregation of Revenue
Net revenues		405	158	0
Neuroscience \| Qulipta \| International
Disaggregation of Revenue
Net revenues		3	0	0
Neuroscience \| Other Neuroscience
Disaggregation of Revenue
Net revenues		276	475	685
Neuroscience \| Other Neuroscience \| United States
Disaggregation of Revenue
Net revenues		254	456	667
Neuroscience \| Other Neuroscience \| International
Disaggregation of Revenue
Net revenues		22	19	18
Eye Care \| Lumigan/Ganfort
Disaggregation of Revenue
Net revenues		432	514	579
Eye Care \| Lumigan/Ganfort \| United States
Disaggregation of Revenue
Net revenues		173	242	273
Eye Care \| Lumigan/Ganfort \| International
Disaggregation of Revenue
Net revenues		259	272	306
Eye Care \| Alphagan/Combigan
Disaggregation of Revenue
Net revenues		272	346	529
Eye Care \| Alphagan/Combigan \| United States
Disaggregation of Revenue
Net revenues		121	202	373
Eye Care \| Alphagan/Combigan \| International
Disaggregation of Revenue
Net revenues		151	144	156
Eye Care \| Restasis
Disaggregation of Revenue
Net revenues		436	666	1,290
Eye Care \| Restasis \| United States
Disaggregation of Revenue
Net revenues		382	621	1,234
Eye Care \| Restasis \| International
Disaggregation of Revenue
Net revenues		54	45	56
Eye Care \| Other Eye Care
Disaggregation of Revenue
Net revenues		803	747	751
Eye Care \| Other Eye Care \| United States
Disaggregation of Revenue
Net revenues		433	399	393
Eye Care \| Other Eye Care \| International
Disaggregation of Revenue
Net revenues		370	348	358
Eye Care \| Ozurdex
Disaggregation of Revenue
Net revenues		472	428	418
Eye Care \| Ozurdex \| United States
Disaggregation of Revenue
Net revenues		143	139	130
Eye Care \| Ozurdex \| International
Disaggregation of Revenue
Net revenues		329	289	288
Other Key Products \| Mavyret
Disaggregation of Revenue
Net revenues		1,430	1,541	1,710
Other Key Products \| Mavyret \| United States
Disaggregation of Revenue
Net revenues		659	755	754
Other Key Products \| Mavyret \| International
Disaggregation of Revenue
Net revenues		771	786	956
Other Key Products \| Creon \| United States
Disaggregation of Revenue
Net revenues		1,268	1,278	1,191
Other Key Products \| Linzess/Constella
Disaggregation of Revenue
Net revenues		1,108	1,035	1,038
Other Key Products \| Linzess/Constella \| United States
Disaggregation of Revenue
Net revenues		1,073	1,003	1,006
Other Key Products \| Linzess/Constella \| International
Disaggregation of Revenue
Net revenues		$ 35	$ 32	$ 32